An agreement has been formed by 3N Diagnostics and Fortress Diagnostics for the manufacture of the novel and patented breast cancer test, the Avisio FOXC1.
Breast cancer ribbon
The test, which has already obtained a CE Mark, works by detecting a biomarker that is unique to an aggressive form of breast cancer, basal-like breast cancer (BLBC), and will assist healthcare professionals to diagnose this form of the disease in patients. BLBC is notoriously difficult to diagnose, with most patients not finding out they have the aggressive form of the disease until two to five years after initial diagnosis of breast cancer. This can lead to the patient having a more developed disease and can compromise treatment efficacy.
Dr Roberto Fagnani, CEO of 3N Diagnostics, said: “This agreement will provide 3N Diagnostics with access to a highly qualified scientific team with a strong track record for the production of the new Avisio FOXC1 test for BLBC,” he said.
“The Avisio FOXC1 test is a novel product, which will help revolutionise breast cancer diagnosis,” added Dr Morteza Afrasiabi, managing director of Fortress Diagnostics. “We are immensely proud to be at the centre of manufacturing it for worldwide distribution.”
The FOXC1 test is expected to launch commercially throughout the EU next month.
3N Diagnostics is a privately-owned company that is an affiliate of the US company Onconostic Technologies. Fortress Diagnostics is a primary manufacturer of medical diagnostics.